Pfizer Korea said it has signed a co-promotion agreement with Korea Vaccine Sales for Prevenar 20, a pneumococcal conjugate vaccine containing the highest number of serotypes among all pneumococcal conjugate vaccines approved in Korea.

Korea Vaccine Sales is a private manufacturer of prophylactics and medical devices. 

Prevenar 20, which received marketing approval from the Ministry of Food and Drug Safety on Oct. 31, 2024. The vaccine is indicated for the prevention of invasive disease, pneumonia, and acute otitis media caused by pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in infants and children aged six weeks to under 18 years. It is also approved for the prevention of invasive disease and pneumonia caused by these serotypes in adults aged 18 and older.

This new partnership builds on the strategic collaboration established in 2013 between the two companies. With a strong track record of jointly promoting Prevenar 13, which has been the top-selling pneumococcal vaccine for infants in Korea for 14 consecutive years according to IQVIA, Pfizer Korea and Korea Vaccine Sales aim to strengthen their leadership in the pediatric pneumococcal vaccine market through Prevenar 20.

“The strong trust built over 12 years of collaboration with Korea Vaccine Sales has been instrumental in Pfizer Korea’s over 20-year heritage of Prevenar in Korea,” Pfizer Korea Primary Care Therapeutic Area Lead Song Chan-woo said. “This renewed partnership marks the beginning of another meaningful collaboration that will further enhance the value of pneumococcal vaccination.”

Korea Vaccine Sales CEO Ha Sung-bae said, “We are delighted to provide the newly launched Prevenar 20 to more infants through this co-promotion agreement.”

The company hopes this partnership serves as a stepping stone for continuous collaboration between the two companies and a milestone in improving public health, Ha added.